Oral Anticoagulant Discontinuation, Adherence Patterns, Hospitalizations and Costs in Non-Valvular Atrial Fibrillation (NVAF) Patients

Bristol-Myers Squibb (BMS)

Status: Completed

Conditions: Atrial Fibrillation

Treatments: Drug: apixaban; Drug: warfarin; Drug: rivaroxaban; Drug: dabigatran

Study type: Observational

Funder types: Industry

Identifiers

NCT02792335

CV185-412

Details and patient eligibility

About

To describe the rate of discontinuation among Non-Valvular Atrial Fibrillation (NVAF) patients who were on warfarin and have switched to the Novel oral anticoagulants(NOACs).

Enrollment: 28,000 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Individuals with NVAF who were on warfarin and have switched to the NOACs (dabigatran, rivaroxaban and apixaban) within the study period January 01, 2013 through March 31, 2014
• Individuals ≥18 years old on the index date
• At least 1 year of baseline period with history of continuous warfarin use in the baseline period for at least 3 months immediately before the index date
• At least 1 diagnosis of AF in the 12 months prior to index date
• Continuous eligibility with medical and pharmacy benefits for at least 12 months before the index date through 1 month after the index date

Exclusion criteria

• Individuals with a diagnosis of valvular heart disease or cardiac surgery during the 12 months prior to index date

Trial design

28,000 participants in 2 patient groups

patients naive to oral anticoagulant treatment

Description:

NVAF patients naïve to oral anticoagulant treatment (Naïve)

Treatment:

Drug: rivaroxaban

Drug: apixaban

Drug: dabigatran

patients with prior warfarin therapy

Description:

NVAF patients with prior warfarin therapy (Warfarin treated)

Treatment:

Drug: rivaroxaban

Drug: warfarin

Drug: apixaban

Drug: dabigatran